Johnson & Johnson JNJ

$259.36 +5.57 (2.19%)

Valuation

Market cap
611,608,000,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.00
Forward PE
22.99
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
7,664,200
Avg volume
6,832,706
Day's range
$256.42 – $260.77
Shares out
2,409,898,000
Stochastic %K
74%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

TopOptionAlert Oct 21, 6:27 AM
$JNJ NOV20 265C · update Called at $253.79 on Oct 20, now $259.36 (plus 2.19%). The trade is working, with objectives at $265.35, then $281.07, and the invalidation at $245.17. P.S. Slow and steady suits this one fine, as long as it keeps holding its gains into each close.
0 replies
Techdamentals Oct 21, 3:52 AM
$JNJ rose 2.2% on Tuesday Oct 20 as health care stocks hit an all-time high. On Oct 13 it raised its 2026 forecast but booked a one-time charge tied to a proposed talc lawsuit settlement, which cut third-quarter GAAP net earnings to $0.21B, down 95.9%, versus $6.34B adjusted for the charge. Sales were $25.4B, up 5.9%. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator answers from the company's own numbers. What do its fundamentals actually say? 👇 https://techdamentals.com/v3/JNJ?ref=st Educational, not advice.
0 replies
Honest_Abe Oct 21, 3:47 AM
$SPY $QQQ $PFE $JNJ "Team doctors were initially hopeful that Hurts only had a Johnson & Johnson. Unfortunately, follow-up CT scans today showed it's a full-blown Pfizer, and he will need several months to recover." "Losing blood flow is bad," explained Dr. Vijay Gupta.
1 replies
SellasgpsCurativeBAT11 Oct 20, 11:36 PM
$AZN $BMY $JNJ $PFE $SLS I wrote Extensively about the fact that Sellas Headquarters Lease wasn’t Renewed during early October window like per usual occurrence every past year. A review of SEC filings shows SELLAS has extended its 7 Times Square sublease in one-year increments, each signed approximately 12 months before expiration: - December 11, 2023: extended to September 30, 2025 - October 2-3, 2024: extended to September 30, 2026 (8-K filed October 4) - October 1, 2025: extended to September 30, 2027 (8-K filed October 3) Under this pattern, an extension to September 30, 2028 would have been expected on or about October 1, 2026. As of the close on Friday, October 2, 2026 No filing was made. So BO is a foregone conclusion. I wouldn’t be surprised if we get Data+ deal in the same PR! ✌️🙏❤️‍🩹
0 replies
HboFam Oct 20, 8:09 PM
$SLS $JNJ $PFE $AZN who is going to believe this lying skeeze the next time it says it sold all off its SLS
2 replies
SellasgpsCurativeBAT11 Oct 20, 7:56 PM
$SLS $JNJ $PFE $AZN $BMY Looks like Sellas is sold ! ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 20, 7:48 PM
$JNJ $MRNA $SLS Big Pharmaceuticals have paid over $10 Billion this year for phase 1, phase 2 companies. Sellas MC too low with 2 Late stage Platform assets that can generate over $30 Billion annually by 2030. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 20, 7:44 PM
$JNJ $MRNA $SLS Massive orders moving through ASK on Level 2. Over 2.5 million volume in last 35 minutes. ✌️🙏❤️‍🩹
0 replies